Cargando…
Receptor clustering and pathogenic complement activation in myasthenia gravis depend on synergy between antibodies with multiple subunit specificities
Myasthenia gravis is an autoimmune disorder defined by muscle weakness and fatigability associated with antibodies against proteins of the neuromuscular junction (NMJ). The most common autoantibody target is the acetylcholine receptor (AChR). Three mechanisms have been postulated by which autoantibo...
Autores principales: | Rose, Natalie, Holdermann, Sebastian, Callegari, Ilaria, Kim, Hyein, Fruh, Isabelle, Kappos, Ludwig, Kuhle, Jens, Müller, Matthias, Sanderson, Nicholas S. R., Derfuss, Tobias |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9547806/ https://www.ncbi.nlm.nih.gov/pubmed/36074148 http://dx.doi.org/10.1007/s00401-022-02493-6 |
Ejemplares similares
-
Role of complement in myasthenia gravis
por: San, Pyae Phyo, et al.
Publicado: (2023) -
Severe exacerbation of relapsing-remitting multiple sclerosis after G-CSF therapy
por: Rust, Heiko, et al.
Publicado: (2016) -
Complement Inhibitor Therapy for Myasthenia Gravis
por: Albazli, Khaled, et al.
Publicado: (2020) -
Complement Inhibition for the Treatment of Myasthenia Gravis
por: Mantegazza, Renato, et al.
Publicado: (2020) -
Complement deposition at the neuromuscular junction in seronegative myasthenia gravis
por: Hoffmann, Sarah, et al.
Publicado: (2020)